Abstract
Recent evidence suggests that the immune system is involved in the carcinogenesis process and the antitumor immune responses impact the clinical outcome, thus emphasizing the concept of cancer immune surveillance. In this context, dendritic cells (DCs) seem to play a crucial role, as they are the most potent antigen-presenting cells (APCs) and are able to stimulate naive T lymphocytes and to generate memory T lymphocytes. Immunotherapy with DC-based vaccines is a very attractive approach to treat cancer, offering the potential for high tumor-specific cytotoxicity. Although breast cancer (BC) is traditionally considered a poorly immunogenic tumor, increasing numbers of both preclinical and clinical studies demonstrate that vaccination with DCs is capable of inducing an antitumor-specific response, while being well tolerated and safe. However, clinical objective responses are still disappointing and many reasons may explain the difficulty of developing effective DC-based therapies for BC. In this review, we discuss the characteristics of DCs, and the major clinical indications for DC-based immunotherapy in BC with related drawbacks.
| Original language | English |
|---|---|
| Pages (from-to) | 349-360 |
| Number of pages | 12 |
| Journal | Immunotherapy |
| Volume | 6 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2014 |
Fingerprint
Keywords
- breast cancer
- dendritic cells
- immune response
- immunotherapies
- vaccines
ASJC Scopus subject areas
- Immunology and Allergy
- Oncology
- Immunology
- Medicine(all)
Cite this
Dendritic cell-based vaccines : Clinical applications in breast cancer. / Gelao, Lucia; Criscitiello, Carmen; Esposito, Angela; Laurentiis, Michele De; Fumagalli, Luca; Locatelli, Marzia Adelia; Minchella, Ida; Santangelo, Michele; Placido, Sabino De; Goldhirsch, Aron; Curigliano, Giuseppe.
In: Immunotherapy, Vol. 6, No. 3, 2014, p. 349-360.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Dendritic cell-based vaccines
T2 - Clinical applications in breast cancer
AU - Gelao, Lucia
AU - Criscitiello, Carmen
AU - Esposito, Angela
AU - Laurentiis, Michele De
AU - Fumagalli, Luca
AU - Locatelli, Marzia Adelia
AU - Minchella, Ida
AU - Santangelo, Michele
AU - Placido, Sabino De
AU - Goldhirsch, Aron
AU - Curigliano, Giuseppe
PY - 2014
Y1 - 2014
N2 - Recent evidence suggests that the immune system is involved in the carcinogenesis process and the antitumor immune responses impact the clinical outcome, thus emphasizing the concept of cancer immune surveillance. In this context, dendritic cells (DCs) seem to play a crucial role, as they are the most potent antigen-presenting cells (APCs) and are able to stimulate naive T lymphocytes and to generate memory T lymphocytes. Immunotherapy with DC-based vaccines is a very attractive approach to treat cancer, offering the potential for high tumor-specific cytotoxicity. Although breast cancer (BC) is traditionally considered a poorly immunogenic tumor, increasing numbers of both preclinical and clinical studies demonstrate that vaccination with DCs is capable of inducing an antitumor-specific response, while being well tolerated and safe. However, clinical objective responses are still disappointing and many reasons may explain the difficulty of developing effective DC-based therapies for BC. In this review, we discuss the characteristics of DCs, and the major clinical indications for DC-based immunotherapy in BC with related drawbacks.
AB - Recent evidence suggests that the immune system is involved in the carcinogenesis process and the antitumor immune responses impact the clinical outcome, thus emphasizing the concept of cancer immune surveillance. In this context, dendritic cells (DCs) seem to play a crucial role, as they are the most potent antigen-presenting cells (APCs) and are able to stimulate naive T lymphocytes and to generate memory T lymphocytes. Immunotherapy with DC-based vaccines is a very attractive approach to treat cancer, offering the potential for high tumor-specific cytotoxicity. Although breast cancer (BC) is traditionally considered a poorly immunogenic tumor, increasing numbers of both preclinical and clinical studies demonstrate that vaccination with DCs is capable of inducing an antitumor-specific response, while being well tolerated and safe. However, clinical objective responses are still disappointing and many reasons may explain the difficulty of developing effective DC-based therapies for BC. In this review, we discuss the characteristics of DCs, and the major clinical indications for DC-based immunotherapy in BC with related drawbacks.
KW - breast cancer
KW - dendritic cells
KW - immune response
KW - immunotherapies
KW - vaccines
UR - http://www.scopus.com/inward/record.url?scp=84899520319&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84899520319&partnerID=8YFLogxK
U2 - 10.2217/imt.13.169
DO - 10.2217/imt.13.169
M3 - Article
VL - 6
SP - 349
EP - 360
JO - Immunotherapy
JF - Immunotherapy
SN - 1750-743X
IS - 3
ER -